FISH and flow 2014 cuts

LOL @ being "go to lab" - having zero revenue and no savior.

PS - Abbott will not be buying Neo, what is in it for them, clients with just above break even margins?

I dunno ... I've seen stranger things. Abbott could use their lab to for companion diagnostics and "low margin clients" would yeild a nice price for them - especially if they are diversifying their menu with higher margin tests.
 






I predict by November 27th, Neo will be the premier go-to lab for cancer diagnostics--if not nationally, then for sure regionally. The anemic competition will fall by the wayside after CMS issues its final decisions.

We'll all know if I am right shortly.

Totally agree. Soon the LOL crowd will have to eat crow.
 












Our time is almost here. This nonsense about being bought by Quest will be silenced. We don't need to be bought by anyone. Don't listen to these naysayers. They are probably just envious reps from loser labs.